These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

459 related items for PubMed ID: 19418648

  • 1. Fluticasone/salmeterol: labeling change.
    Prescrire Int; 2008 Dec; 17(98):229. PubMed ID: 19418648
    [Abstract] [Full Text] [Related]

  • 2. COPD: don't use fluticasone + salmeterol. Patients treated with inhaled fluticasone for chronic obstructive pulmonary disease (COPD) are more prone to pneumonia.
    Prescrire Int; 2007 Dec; 16(92):257-8. PubMed ID: 18092426
    [No Abstract] [Full Text] [Related]

  • 3. Lower inhaled steroid requirement with a fluticasone/salmeterol combination in family practice patients with asthma or COPD.
    Schermer TR, Albers JM, Verblackt HW, Costongs RJ, Westers P.
    Fam Pract; 2007 Apr; 24(2):181-8. PubMed ID: 17251178
    [Abstract] [Full Text] [Related]

  • 4. [Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial].
    Wouters EF, Postma DS, Fokkens B, Hop WC, Prins J, Kuipers AF, Pasma HR, Hensing CA, Creutzberg EC, Cosmic COPD and Serentide: A Multi-Center Intervention and Characterization Study Group.
    Rev Port Pneumol; 2005 Apr; 11(6):587-9. PubMed ID: 16514718
    [No Abstract] [Full Text] [Related]

  • 5. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease.
    Kardos P, Wencker M, Glaab T, Vogelmeier C.
    Am J Respir Crit Care Med; 2007 Jan 15; 175(2):144-9. PubMed ID: 17053207
    [Abstract] [Full Text] [Related]

  • 6. Combined salmeterol and fluticasone for COPD.
    Vassiliou V.
    Lancet; 2003 May 10; 361(9369):1651; author reply 1652-3. PubMed ID: 12747901
    [No Abstract] [Full Text] [Related]

  • 7. [Debates surrounding COPD].
    Tillie-Leblond I, Housset B.
    Rev Mal Respir; 2010 Feb 10; 27(2):106-7. PubMed ID: 20206057
    [No Abstract] [Full Text] [Related]

  • 8. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations.
    Ferguson GT, Anzueto A, Fei R, Emmett A, Knobil K, Kalberg C.
    Respir Med; 2008 Aug 10; 102(8):1099-108. PubMed ID: 18614347
    [Abstract] [Full Text] [Related]

  • 9. The efficacy and safety of inhaled fluticasone propionate/salmeterol and ipratropium/albuterol for the treatment of chronic obstructive pulmonary disease: an eight-week, multicenter, randomized, double-blind, double-dummy, parallel-group study.
    Make B, Hanania NA, ZuWallack R, Kalberg C, Emmett A, Brown CP, Knobil K.
    Clin Ther; 2005 May 10; 27(5):531-42. PubMed ID: 15978302
    [Abstract] [Full Text] [Related]

  • 10. [A rational combination for the treatment of asthma. Salmeterol and fluticasone in one preparation].
    Wettengel R, Steinkamp G.
    Pneumologie; 1999 Sep 10; 53(9):426-32. PubMed ID: 10544652
    [No Abstract] [Full Text] [Related]

  • 11. [Salmeterol + fluticasone in COPD. Complementary treatment principles hold true in the COPD management, too].
    MMW Fortschr Med; 2003 Nov 13; 145(46):47. PubMed ID: 14699834
    [No Abstract] [Full Text] [Related]

  • 12. Predictive factors for evaluation of response to fluticasone propionate/salmeterol combination in severe COPD.
    Tonnel AB, Tillie-Leblond I, Attali V, Bavelele Z, Lagrange O.
    Respir Med; 2011 Feb 13; 105(2):250-8. PubMed ID: 20702076
    [Abstract] [Full Text] [Related]

  • 13. Management of chronic obstructive pulmonary disease: moving beyond the asthma algorithm.
    Gordon E, Lazarus SC.
    J Allergy Clin Immunol; 2009 Nov 13; 124(5):873-80; quiz 881-2. PubMed ID: 19895979
    [Abstract] [Full Text] [Related]

  • 14. [Chronic obstructive pulmonary disease. No increased survival with combination therapy].
    Ecker-Schlipf B.
    Med Monatsschr Pharm; 2007 Nov 13; 30(11):428-9. PubMed ID: 18062342
    [No Abstract] [Full Text] [Related]

  • 15. TORCH and UPLIFT: what has been learned from the COPD "mega-trials"?
    Niewoehner DE.
    COPD; 2009 Feb 13; 6(1):1-3. PubMed ID: 19229702
    [Abstract] [Full Text] [Related]

  • 16. Combination therapy with the single inhaler salmeterol/fluticasone propionate versus increased doses of inhaled corticosteroids in patients with asthma.
    Li HT, Zhang TT, Zhou H, Qu XJ, Wu WM, Huang J.
    Respiration; 2007 Feb 13; 74(1):33-43. PubMed ID: 17008769
    [Abstract] [Full Text] [Related]

  • 17. Changes in lung function and health status in patients with COPD treated with tiotropium or salmeterol plus fluticasone.
    Kurashima K, Hara K, Yoneda K, Kanauchi T, Kagiyama N, Tokunaga D, Takayanagi N, Ubukata M, Sugita Y.
    Respirology; 2009 Mar 13; 14(2):239-44. PubMed ID: 19210650
    [Abstract] [Full Text] [Related]

  • 18. A double-blind crossover study comparing the safety and efficacy of three weeks of Flu/Sal 250/50 bid plus albuterol 180 ug prn q4 hours to Flu/Sal 250/50 bid plus albuterol/Ipratropium bromide 2 puffs prn q4 hours in patients with chronic obstructive pulmonary disease.
    Balkissoon R, Make B.
    COPD; 2008 Aug 13; 5(4):221-7. PubMed ID: 18671147
    [Abstract] [Full Text] [Related]

  • 19. [Inhalation of beta-2 agonists or corticosteroids as single drugs in comparison with combination therapy of patients with COPD].
    Steurer-Stey C.
    Praxis (Bern 1994); 2003 Jul 30; 92(31-32):1324-5. PubMed ID: 12934343
    [No Abstract] [Full Text] [Related]

  • 20. Does low-dose seretide reverse chronic obstructive pulmonary disease and are the benefits sustained over time? An open-label Swedish crossover cohort study between 1999 and 2005.
    Rustscheff S, Rydén L.
    J Asthma; 2010 Mar 30; 47(2):214-6. PubMed ID: 20170332
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.